{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:51:25Z","timestamp":1793641885862,"version":"4.5.1"},"reference-count":182,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.pharmthera.2022.108116","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T14:37:10Z","timestamp":1642603030000},"page":"108116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"special_numbering":"C","title":["Endothelial dysfunction as a complication of anti-cancer therapy"],"prefix":"10.1016","volume":"237","author":[{"given":"Jan\u00e9e D.","family":"Terwoord","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas M.","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Gutterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.pharmthera.2022.108116_bb0005","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/sj.bjc.6601022","article-title":"The new cardioprotector Monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro","volume":"89","author":"Abou El Hassan","year":"2003","journal-title":"British Journal of Cancer"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108116_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.119.013754","article-title":"Reverse cardio-oncology: Cancer development in patients With cardiovascular disease","volume":"9","author":"Aboumsallem","year":"2020","journal-title":"Journal of the American Heart Association"},{"issue":"24","key":"10.1016\/j.pharmthera.2022.108116_bb0015","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1016\/j.jacc.2017.09.1140","article-title":"Flow-mediated dilation of brachial artery as a screening tool for anthracycline-induced cardiotoxicity","volume":"70","author":"Anastasiou","year":"2017","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-065X.2007.00573.x","article-title":"The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy","volume":"220","author":"Apetoh","year":"2007","journal-title":"Immunological Reviews"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108116_bb0025","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0030","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.freeradbiomed.2021.04.021","article-title":"Oxidative stress in anticancer therapies-related cardiac dysfunction","volume":"169","author":"Attanasio","year":"2021","journal-title":"Free Radical Biology and Medicine"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0035","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41419-020-02985-x","article-title":"NLRP3 inflammasome in endothelial dysfunction","volume":"11","author":"Bai","year":"2020","journal-title":"Cell Death & Disease"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108116_bb0040","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/01.CIR.0000090690.67322.51","article-title":"Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes","volume":"108","author":"Baldus","year":"2003","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108116_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023492","article-title":"In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels","volume":"6","author":"Bar-Joseph","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108116_bb0050","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00018-018-2956-z","article-title":"Pathological effects of ionizing radiation: Endothelial activation and dysfunction","volume":"76","author":"Baselet","year":"2019","journal-title":"Cellular and Molecular Life Sciences"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108116_bb0055","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/00003495-199957040-00003","article-title":"Cardiotoxicity of the antiproliferative compound fluorouracil","volume":"57","author":"Becker","year":"1999","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0060","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00395-016-0594-x","article-title":"Transition in the mechanism of flow-mediated dilation with aging and development of coronary artery disease","volume":"112","author":"Beyer","year":"2017","journal-title":"Basic Research in Cardiology"},{"issue":"17","key":"10.1016\/j.pharmthera.2022.108116_bb0065","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa035003","article-title":"Prognostic value of myeloperoxidase in patients with chest pain","volume":"349","author":"Brennan","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0070","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1161\/HYPERTENSIONAHA.119.12881","article-title":"Strong relationship between vascular function in the coronary and brachial arteries","volume":"74","author":"Broxterman","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0075","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/sj.bjc.6603640","article-title":"Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice","volume":"96","author":"Bruynzeel","year":"2007","journal-title":"British Journal of Cancer"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108116_bb0080","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1089\/ars.2020.8055","article-title":"Antioxidant approach as a cardioprotective strategy in chemotherapy-induced cardiotoxicity","volume":"34","author":"Cadeddu Dessalvi","year":"2021","journal-title":"Antioxidants and Redox Signaling"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108116_bb0085","first-page":"443","article-title":"Comprehensive characterization of the vascular effects of cisplatin-based chemotherapy in patients with testicular cancer","volume":"2","author":"Cameron","year":"2020","journal-title":"JACC: Cardiooncology"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108116_bb0090","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.cjca.2015.12.023","article-title":"Vascular complications of cancer chemotherapy","volume":"32","author":"Cameron","year":"2016","journal-title":"Canadian Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0095","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11936-016-0465-7","article-title":"Exercise and aerobic fitness to reduce cancer-related cardiovascular toxicity","volume":"18","author":"Campia","year":"2016","journal-title":"Current Treatment Options in Cardiovascular Medicine"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0100","doi-asserted-by":"crossref","first-page":"8863789","DOI":"10.1155\/2021\/8863789","article-title":"Role of oxidative stress in the mechanisms of anthracycline-induced cardiotoxicity: Effects of preventive strategies","volume":"2021","author":"Carrasco","year":"2021","journal-title":"Oxidative Medicine and Cellular Longevity"},{"issue":"8828","key":"10.1016\/j.pharmthera.2022.108116_bb0105","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/0140-6736(92)93147-F","article-title":"Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis","volume":"340","author":"Celermajer","year":"1992","journal-title":"The Lancet"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0110","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3389\/fphar.2020.00557","article-title":"Immune checkpoint inhibitor-related cytokine release syndrome: Analysis of WHO global pharmacovigilance database","volume":"11","author":"Ceschi","year":"2020","journal-title":"Frontiers in Pharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108116_bb0115","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.2005.03.5956","article-title":"Anthracyclines cause endothelial injury in pediatric cancer patients: A pilot study","volume":"24","author":"Chow","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108116_bb0120","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1161\/HYPERTENSIONAHA.120.16759","article-title":"Tumor necrosis factor alpha-mediated inflammation and remodeling of the extracellular matrix underlies aortic stiffening induced by the common chemotherapeutic agent doxorubicin","volume":"77","author":"Clayton","year":"2021","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108116_bb0125","first-page":"475","article-title":"Doxorubicin-induced oxidative stress and endothelial dysfunction in conduit arteries is prevented by mitochondrial-specific antioxidant treatment","volume":"2","author":"Clayton","year":"2020","journal-title":"JACC: Cardiooncology"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3389\/fcvm.2021.651594","article-title":"Microvascular structural alterations in patients treated with antiangiogenic drugs","volume":"8","author":"Coschignano","year":"2021","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108116_bb0135","first-page":"805","article-title":"The appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits","volume":"10","author":"Cwikiel","year":"1996","journal-title":"Scanning Microscopy"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108116_bb0140","first-page":"561","article-title":"The influence of 5-fluorouracil on the endothelium in small arteries. An electron microscopic study in rabbits","volume":"9","author":"Cwikiel","year":"1995","journal-title":"Scanning Microscopy"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108116_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11886-020-01377-z","article-title":"Sex-related differences in dilated cardiomyopathy with a focus on cardiac dysfunction in oncology","volume":"22","author":"D\u2019Amario","year":"2020","journal-title":"Current Cardiology Reports"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108116_bb0150","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/cam4.1019","article-title":"Dasatinib inhibits actin fiber reorganization and promotes endothelial cell permeability through RhoA-ROCK pathway","volume":"6","author":"Dasgupta","year":"2017","journal-title":"Cancer Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108116_bb0155","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.ejca.2003.11.026","article-title":"Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy: Cardiovascular risk factors and signs of vascular damage","volume":"40","author":"De Vos","year":"2004","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108116_bb0160","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014708","article-title":"Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction","volume":"9","author":"Demissei","year":"2020","journal-title":"Journal of the American Heart Association"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0165","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/MPH.0b013e318159a593","article-title":"Endothelial function in young adult survivors of childhood acute lymphoblastic leukemia","volume":"30","author":"Dengel","year":"2008","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0170","first-page":"1","article-title":"Oxidant stress in mitochondrial DNA damage, autophagy and inflammation in atherosclerosis","volume":"3","author":"Ding","year":"2013","journal-title":"Scientific Reports 2013 3:1"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0175","article-title":"Coronary vasomotor dysfunction portends worse outcomes in patients with breast cancer","author":"Divakaran","year":"2021","journal-title":"Journal of Nuclear Cardiology"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0180","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108116_bb0185","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1191\/1358863x03vm476oa","article-title":"Rapid-onset endothelial dysfunction with adriamycin: Evidence for a dysfunctional nitric oxide synthase","volume":"8","author":"Duquaine","year":"2003","journal-title":"Vascular Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108116_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/micc.12625","article-title":"BCR-ABL tyrosine kinase inhibitors promote pathological changes in dilator phenotype in the human microvasculature","volume":"27","author":"Durand","year":"2020","journal-title":"Microcirculation"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0147691","article-title":"Influence of adjuvant therapy in cancer survivors on endothelial function and skeletal muscle deoxygenation","volume":"11","author":"Ederer","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0200","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3389\/fphys.2018.00537","article-title":"Rho-kinase inhibition ameliorates dasatinib-induced endothelial dysfunction and pulmonary hypertension","volume":"9","author":"Fazakas","year":"2018","journal-title":"Frontiers in Physiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108116_bb0205","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jacc.2017.05.019","article-title":"Arginine-nitric oxide metabolites and cardiac dysfunction in patients with breast cancer","volume":"70","author":"Finkelman","year":"2017","journal-title":"Journal of the American College of Cardiology"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108116_bb0210","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1182\/blood-2002-05-1300","article-title":"Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells","volume":"101","author":"Fiuza","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0215","article-title":"Changes in vascular function during breast cancer treatment","volume":"1\u201311","author":"Fredslund","year":"2021","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0220","first-page":"1","article-title":"Coronary microcirculation damage in anthracycline cardiotoxicity","volume":"0","author":"Gal\u00e1n-Arriola","year":"2021","journal-title":"Cardiovascular Research"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108116_bb0225","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.bbamcr.2016.01.021","article-title":"New signal transduction paradigms in anthracycline-induced cardiotoxicity","volume":"1863","author":"Ghigo","year":"2016","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0230","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ijcard.2016.11.025","article-title":"Endothelial dysfunction and cardiovascular risk factors in childhood acute lymphoblastic leukemia survivors","volume":"228","author":"Giordano","year":"2017","journal-title":"International Journal of Cardiology"},{"issue":"13","key":"10.1016\/j.pharmthera.2022.108116_bb0235","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1161\/01.CIR.0000012543.55874.47","article-title":"Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: A prospective study","volume":"105","author":"Gokce","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108116_bb0240","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00262-010-0931-0","article-title":"Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence","volume":"60","author":"Gonz\u00e1lez-Reyes","year":"2011","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0245","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/ATVBAHA.120.314378","article-title":"Cancer therapy-associated thrombosis","volume":"41","author":"Grover","year":"2021","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108116_bb0250","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discovery"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108116_bb0255","doi-asserted-by":"crossref","first-page":"H705","DOI":"10.1152\/ajpheart.00370.2019","article-title":"Detrimental effects of chemotherapy on human coronary microvascular function","volume":"317","author":"Hader","year":"2019","journal-title":"American Journal of Physiology - Heart and Circulatory Physiology"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0260","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10.1016\/j.pharmthera.2022.108116_bb0265","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0270","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1038\/s41467-020-19970-9","article-title":"Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death","volume":"11","author":"Hayashi","year":"2020","journal-title":"Nature Communications"},{"issue":"15 Suppl","key":"10.1016\/j.pharmthera.2022.108116_bb0275","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.2020.38.15_suppl.1044","article-title":"Peripheral endothelial function changes during HER2-directed therapy differ based on whether or not a patient receives anthracycline","volume":"38","author":"Hazim","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0280","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.3389\/fphar.2019.01531","article-title":"Doxorubicin induces endotheliotoxicity and mitochondrial dysfunction via ROS\/eNOS\/NO pathway","volume":"10","author":"He","year":"2019","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0285","doi-asserted-by":"crossref","first-page":"8157640","DOI":"10.1155\/2020\/8157640","article-title":"Despite blocking doxorubicin-induced vascular damage, quercetin ameliorates its antibreast cancer activity","volume":"2020","author":"Henidi","year":"2020","journal-title":"Oxidative Medicine and Cellular Longevity"},{"issue":"46","key":"10.1016\/j.pharmthera.2022.108116_bb0290","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1038\/onc.2016.104","article-title":"Damage-associated molecular patterns in cancer: A double-edged sword","volume":"35","author":"Hernandez","year":"2016","journal-title":"Oncogene"},{"issue":"13","key":"10.1016\/j.pharmthera.2022.108116_bb0295","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.115.018347","article-title":"Vascular toxicities of cancer therapies: The old and the new - an evolving avenue","volume":"133","author":"Herrmann","year":"2016","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40959-021-00100-3","article-title":"Damage to cardiac vasculature may be associated with breast cancer treatment-induced cardiotoxicity","volume":"7","author":"Hoffman","year":"2021","journal-title":"Cardio-Oncology"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108116_bb0305","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/eurpub\/ckab146","article-title":"Gender aspects in cardiooncology","volume":"31","author":"Hohneck","year":"2021","journal-title":"European Journal of Public Health"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108116_bb0310","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002947","article-title":"Toll-like receptor (TLR)4 and MyD88 are essential for atheroprotection by peritoneal B1a B cells","volume":"5","author":"Hosseini","year":"2016","journal-title":"Journal of the American Heart Association"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108116_bb0315","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.21037\/tlcr-21-92","article-title":"Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer","volume":"10","author":"Inoue","year":"2021","journal-title":"Translational Lung Cancer Research"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108116_bb0320","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019247","article-title":"Chronic inhibition of toll-like receptor 9 ameliorates pulmonary hypertension in rats","volume":"10","author":"Ishikawa","year":"2021","journal-title":"Journal of the American Heart Association"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0325","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1538-7836.2006.02255.x","article-title":"High-mobility group box 1 protein promotes development of microvascular thrombosis in rats","volume":"5","author":"Ito","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108116_bb0330","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/pbc.24565","article-title":"Endothelial function in long-term survivors of childhood acute lymphoblastic leukemia: Effects of a home-based exercise program","volume":"60","author":"J\u00e4rvel\u00e4","year":"2013","journal-title":"Pediatric Blood & Cancer"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108116_bb0335","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s12253-012-9589-6","article-title":"Anthracycline causes impaired vascular endothelial function and aortic stiffness in long term survivors of childhood cancer","volume":"19","author":"Jenei","year":"2013","journal-title":"Pathology and Oncology Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108116_bb0340","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1161\/01.CIR.91.5.1314","article-title":"Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo","volume":"91","author":"Joannides","year":"1995","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108116_bb0345","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1158\/1940-6207.CAPR-12-0416","article-title":"Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy","volume":"6","author":"Jones","year":"2013","journal-title":"Cancer Prevention Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108116_bb0350","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1158\/1055-9965.EPI-06-0870","article-title":"Cardiovascular risk profile of patients with HER2\/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and\/or trastuzumab","volume":"16","author":"Jones","year":"2007","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"issue":"5\u20136","key":"10.1016\/j.pharmthera.2022.108116_bb0355","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/10623320490904124","article-title":"Differential toxicity of antracyclines on cultured endothelial cells","volume":"11","author":"Kaushal","year":"2004","journal-title":"Endothelium: Journal of Endothelial Cell Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108116_bb0360","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/1753944717729141","article-title":"Out of the frying pan and into the fire: Damage-associated molecular patterns and cardiovascular toxicity following cancer therapy","volume":"11","author":"Klee","year":"2017","journal-title":"Therapeutic Advances in Cardiovascular Disease"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108116_bb0365","first-page":"1452","article-title":"Myocardial infarction accelerates breast cancer via innate immune reprogramming","volume":"26","author":"Koelwyn","year":"2020","journal-title":"Nature Medicine 2020 26:9"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108116_bb0370","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108116_bb0375","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nri2215","article-title":"How dying cells alert the immune system to danger","volume":"8","author":"Kono","year":"2008","journal-title":"Nature Reviews Immunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0380","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-014-0266-7","article-title":"Endothelial perturbations and therapeutic strategies in normal tissue radiation damage","volume":"9","author":"Korpela","year":"2014","journal-title":"Radiation Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0385","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10741-018-9731-y","article-title":"Cardio-oncology: A new and developing sector of research and therapy in the field of cardiology","volume":"24","author":"Kostakou","year":"2019","journal-title":"Heart Failure Reviews"},{"issue":"21","key":"10.1016\/j.pharmthera.2022.108116_bb0390","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1158\/1078-0432.CCR-16-0667","article-title":"Dasatinib reversibly disrupts endothelial vascular integrity by increasing non-muscle myosin II contractility in a ROCK-dependent manner","volume":"23","author":"Kreutzman","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0395","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.cbi.2015.05.013","article-title":"Febuxostat ameliorates doxorubicin-induced cardiotoxicity in rats","volume":"237","author":"Krishnamurthy","year":"2015","journal-title":"Chemico-Biological Interactions"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108116_bb0400","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/cdd.2011.4","article-title":"TLR-2 and TLR-9 are sensors of apoptosis in a mouse model of doxorubicin-induced acute inflammation","volume":"18","author":"Krysko","year":"2011","journal-title":"Cell Death & Differentiation 2011 18:8"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108116_bb0405","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nature Reviews Cancer"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108116_bb0410","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108116_bb0415","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1002\/cam4.2910","article-title":"Effects of sunitinib on endothelial dysfunction, metabolic changes, and cardiovascular risk indices in renal cell carcinoma","volume":"9","author":"Lai","year":"2020","journal-title":"Cancer Medicine"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0420","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10549-019-05332-7","article-title":"Effects of high-intensity interval training on vascular endothelial function and vascular wall thickness in breast cancer patients receiving anthracycline-based chemotherapy: A randomized pilot study","volume":"177","author":"Lee","year":"2019","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0425","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fcvm.2018.00151","article-title":"Endothelial\u2013vascular smooth muscle cells interactions in atherosclerosis","volume":"5","author":"Li","year":"2018","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108116_bb0430","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1161\/ATVBAHA.112.301087","article-title":"Toll-like receptor 4 mutation protects obese mice against endothelial dysfunction by decreasing NADPH oxidase isoforms 1 and 4","volume":"33","author":"Liang","year":"2013","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108116_bb0435","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/cvr\/cvz058","article-title":"Inflammation: A common contributor to cancer, aging, and cardiovascular diseases - expanding the concept of cardio-oncology","volume":"115","author":"Libby","year":"2019","journal-title":"Cardiovascular Research"},{"issue":"23","key":"10.1016\/j.pharmthera.2022.108116_bb0440","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Inflammation in atherosclerosis. from pathophysiology to practice","volume":"54","author":"Libby","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108116_bb0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040763","article-title":"Toll-like receptor (TLR) 2 and TLR4 differentially regulate doxorubicin induced cardiomyopathy in mice","volume":"7","author":"Ma","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0450","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10456-009-9134-8","article-title":"A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents","volume":"12","author":"Mabeta","year":"2009","journal-title":"Angiogenesis"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108116_bb0455","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ijc.20249","article-title":"Increased expression of inducible HSP70 in apoptotic cells is correlated with their efficacy for antitumor vaccine therapy","volume":"111","author":"Mass\u00e9","year":"2004","journal-title":"International Journal of Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0460","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/HYPERTENSIONAHA.110.168120","article-title":"Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans","volume":"58","author":"Mayer","year":"2011","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108116_bb0465","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1161\/HYPERTENSIONAHA.118.11782","article-title":"Paying the toll for inflammation: Immunoreceptor-mediated vascular dysfunction in hypertension","volume":"73","author":"McCarthy","year":"2019","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108116_bb0470","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1152\/ajpheart.00328.2013","article-title":"Toll-like receptors and damage-associated molecular patterns: Novel links between inflammation and hypertension","volume":"306","author":"McCarthy","year":"2014","journal-title":"American Journal of Physiology - Heart and Circulatory Physiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108116_bb0475","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ajh\/hpw113","article-title":"Chloroquine suppresses the development of hypertension in spontaneously hypertensive rats","volume":"30","author":"McCarthy","year":"2017","journal-title":"American Journal of Hypertension"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0480","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/cvr\/cvv137","article-title":"Circulating mitochondrial DNA and Toll-like receptor 9 are associated with vascular dysfunction in spontaneously hypertensive rats","volume":"107","author":"McCarthy","year":"2015","journal-title":"Cardiovascular Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108116_bb0485","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/01893697-200119020-00016","article-title":"Cardiovascular morbidity in long-term survivors of metastatic testicular cancer","volume":"19","author":"Meinardi","year":"2001","journal-title":"Rehabilitation Oncology"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108116_bb0490","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/ctrv.2000.0175","article-title":"Long-term chemotherapy-related cardiovascular morbidity","volume":"26","author":"Meinardi","year":"2000","journal-title":"Cancer Treatment Reviews"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0495","doi-asserted-by":"crossref","DOI":"10.1186\/s13293-018-0198-2","article-title":"Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity","volume":"9","author":"Meiners","year":"2018","journal-title":"Biology of Sex Differences"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108116_bb0500","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1161\/01.RES.0000054200.44505.AB","article-title":"Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles","volume":"92","author":"Miura","year":"2003","journal-title":"Circulation Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40959-016-0010-6","article-title":"Targeting endothelial cell metabolism for cardio-protection from the toxicity of antitumor agents","volume":"2","author":"Morbidelli","year":"2016","journal-title":"Cardio-Oncology"},{"issue":"13","key":"10.1016\/j.pharmthera.2022.108116_bb0510","first-page":"3028","article-title":"In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle","volume":"53","author":"Mosseri","year":"1993","journal-title":"Cancer Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108116_bb0515","doi-asserted-by":"crossref","first-page":"994","DOI":"10.5551\/jat.RV17027","article-title":"Mechanism and management of cancer chemotherapy-induced atherosclerosis","volume":"25","author":"Mukai","year":"2018","journal-title":"Journal of Atherosclerosis and Thrombosis"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108116_bb0520","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s12265-012-9358-7","article-title":"Vascular injury in cancer survivors","volume":"5","author":"Mulrooney","year":"2012","journal-title":"Journal of Cardiovascular Translational Research"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0525","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b4606","article-title":"Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the childhood cancer survivor study cohort","volume":"339","author":"Mulrooney","year":"2009","journal-title":"British Medical Journal"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108116_bb0530","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00109-009-0463-2","article-title":"Regulation of vascular integrity","volume":"87","author":"Murakami","year":"2009","journal-title":"Journal of Molecular Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108116_bb0535","first-page":"87","article-title":"A method for detection of doxorubicin-induced cardiotoxicity: Flow-mediated vasodilation of the brachial artery","volume":"6","author":"Nagy","year":"2001","journal-title":"Experimental and Clinical Cardiology"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108116_bb0540","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1161\/01.ATV.0000163262.83456.6d","article-title":"Myeloperoxidase and cardiovascular disease","volume":"25","author":"Nicholls","year":"2005","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"18","key":"10.1016\/j.pharmthera.2022.108116_bb0545","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1161\/01.CIR.0000146889.46519.27","article-title":"Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice","volume":"110","author":"Nozaki","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0550","first-page":"247","article-title":"Vascular damage in testicular cancer patients: A study on endothelial activation by bleomycin and cisplatin in vitro","volume":"23","author":"Nuver","year":"2010","journal-title":"Oncology Reports"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108116_bb0555","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ejca.2003.12.012","article-title":"Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer","volume":"40","author":"Nuver","year":"2004","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2022.108116_bb5000","doi-asserted-by":"crossref","first-page":"9130","DOI":"10.1200\/JCO.2005.01.4092","article-title":"Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer","volume":"23","author":"Nuver","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0560","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nature Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108116_bb0565","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/cam4.2813","article-title":"Causes of death among cancer patients in the era of cancer survivorship in Korea: Attention to the suicide and cardiovascular mortality","volume":"9","author":"Oh","year":"2020","journal-title":"Cancer Medicine"},{"issue":"7397","key":"10.1016\/j.pharmthera.2022.108116_bb0570","first-page":"251","article-title":"Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure","volume":"485","author":"Oka","year":"2012","journal-title":"Nature 2012 485:7397"},{"issue":"26","key":"10.1016\/j.pharmthera.2022.108116_bb0575","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1200\/JCO.2018.78.3290","article-title":"Sex differences in efficacy and toxicity of systemic treatments: An undervalued issue in the era of precision oncology","volume":"36","author":"\u00d6zdemir","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108116_bb0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0184174","article-title":"Cardiovascular disease and mortality after breast cancer in postmenopausal women: Results from the Women\u2019s Health Initiative","volume":"12","author":"Park","year":"2017","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.pharmthera.2022.108116_bb0585","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015598","article-title":"Anticancer therapy-related increases in arterial stiffness: A systematic review and meta-analysis","volume":"9","author":"Parr","year":"2020","journal-title":"Journal of the American Heart Association"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108116_bb0590","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2901","article-title":"Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: A retrospective cohort study","volume":"13","author":"Patnaik","year":"2011","journal-title":"Breast Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0595","doi-asserted-by":"crossref","first-page":"1701096","DOI":"10.1183\/13993003.01096-2017","article-title":"Dasatinib increases endothelial permeability leading to pleural effusion","volume":"51","author":"Phan","year":"2018","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0600","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1152\/ajpheart.00819.2006","article-title":"The mechanism of flow-induced dilation in human adipose arterioles involves hydrogen peroxide during CAD","volume":"292","author":"Phillips","year":"2007","journal-title":"American Journal of Physiology - Heart and Circulatory Physiology"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108116_bb0605","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.108.804294","article-title":"Nuclear factor-\u03baB activation contributes to vascular endothelial dysfunction via oxidative stress in overweight\/obese middle-aged and older humans","volume":"119","author":"Pierce","year":"2009","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108116_bb0610","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1373\/clinchem.2015.241232","article-title":"Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab","volume":"61","author":"Putt","year":"2015","journal-title":"Clinical Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0615","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2162-3619-1-10","article-title":"Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: A meta-analysis","volume":"1","author":"Rafiyath","year":"2012","journal-title":"Experimental Hematology & Oncology"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108116_bb0620","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/1535-7163.MCT-12-1019","article-title":"TLR4 is a novel determinant of the response to paclitaxel in breast cancer","volume":"12","author":"Rajput","year":"2013","journal-title":"Molecular Cancer Therapeutics"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108116_bb0625","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.pharmthera.2009.10.002","article-title":"Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy","volume":"125","author":"Raschi","year":"2010","journal-title":"Pharmacology and Therapeutics"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108116_bb0630","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejheart.2008.01.004","article-title":"Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice","volume":"10","author":"Riad","year":"2008","journal-title":"European Journal of Heart Failure"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108116_bb0635","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0640","doi-asserted-by":"crossref","first-page":"14637","DOI":"10.1038\/s41598-021-94127-2","article-title":"Arterial hypertension assessment in a population with chronic myeloid leukemia","volume":"11","author":"Roa-Chamorro","year":"2021","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108116_bb0645","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/life11020105","article-title":"Molecules and mechanisms to overcome oxidative stress inducing cardiovascular disease in cancer patients","volume":"11","author":"Sabbatino","year":"2021","journal-title":"Life"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108116_bb0650","doi-asserted-by":"crossref","first-page":"H1","DOI":"10.1152\/ajpheart.00756.2018","article-title":"Chemotherapy acutely impairs neurovascular and hemodynamic responses in women with breast cancer","volume":"317","author":"Sales","year":"2019","journal-title":"American Journal of Physiology - Heart and Circulatory Physiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0655","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/13697137.2010.522278","article-title":"Impact of platinum-based chemotherapy on the progression of atherosclerosis","volume":"14","author":"Sekijima","year":"2011","journal-title":"Climacteric"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0660","doi-asserted-by":"crossref","first-page":"E138","DOI":"10.1161\/ATVBAHA.120.314330","article-title":"Vascular endothelial cells and innate immunity","volume":"40","author":"Shao","year":"2020","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0665","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0670","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0675","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1734-1140(09)70018-0","article-title":"Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron","volume":"61","author":"\u0160im\u016fnek","year":"2009","journal-title":"Pharmacological Reports"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0680","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","article-title":"Doxorubicin-induced cardiomyopathy","volume":"339","author":"Singal","year":"1998","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0685","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-06964-5","article-title":"Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells","volume":"20","author":"Solari","year":"2020","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108116_bb0690","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/14779072.2019.1691528","article-title":"Aortic wall stiffness as a side-effect of anti-cancer medication","volume":"17","author":"Solomou","year":"2019","journal-title":"Expert Review of Cardiovascular Therapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108116_bb0695","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ctrv.2011.09.002","article-title":"Endothelial vascular toxicity from chemotherapeutic agents: Preclinical evidence and clinical implications","volume":"38","author":"Soultati","year":"2012","journal-title":"Cancer Treatment Reviews"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108116_bb0700","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.immuni.2013.02.009","article-title":"Abnormal high-density lipoprotein induces endothelial dysfunction via activation of toll-like receptor-2","volume":"38","author":"Speer","year":"2013","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108116_bb0705","doi-asserted-by":"crossref","first-page":"H1569","DOI":"10.1152\/ajpheart.00396.2018","article-title":"Sex differences in endothelial function important to vascular health and overall cardiovascular disease risk across the lifespan","volume":"315","author":"Stanhewicz","year":"2018","journal-title":"American Journal of Physiology - Heart and Circulatory Physiology"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108116_bb0710","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1158\/1078-0432.CCR-07-5050","article-title":"Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor","volume":"14","author":"Steeghs","year":"2008","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108116_bb0715","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/annonc\/mdp417","article-title":"Reversibility of capillary density after discontinuation of bevacizumab treatment","volume":"21","author":"Steeghs","year":"2010","journal-title":"Annals of Oncology"},{"issue":"21","key":"10.1016\/j.pharmthera.2022.108116_bb0720","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1136\/heartjnl-2020-318083","article-title":"Cardiotoxicities of novel cancer immunotherapies","volume":"107","author":"Stein-Merlob","year":"2021","journal-title":"Heart"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108116_bb0725","doi-asserted-by":"crossref","first-page":"11324","DOI":"10.3390\/ijms150711324","article-title":"Endothelial dysfunction in chronic inflammatory diseases","volume":"15","author":"Steyers","year":"2014","journal-title":"International Journal of Molecular Sciences"},{"issue":"48","key":"10.1016\/j.pharmthera.2022.108116_bb0730","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","article-title":"A population-based study of cardiovascular disease mortality risk in US cancer patients","volume":"40","author":"Sturgeon","year":"2019","journal-title":"European Heart Journal"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108116_bb0735","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/annonc\/mdh150","article-title":"5-Fluorouracil induces arterial vasocontractions","volume":"15","author":"S\u00fcdhoff","year":"2004","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108116_bb0740","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059989","article-title":"Mitochondrial DAMPs increase endothelial permeability through neutrophil dependent and independent pathways","volume":"8","author":"Sun","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108116_bb0745","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1152\/japplphysiol.00394.2018","article-title":"Lower cutaneous microvascular reactivity in adult cancer patients receiving chemotherapy","volume":"125","author":"Sutterfield","year":"2018","journal-title":"Journal of Applied Physiology"},{"issue":"48","key":"10.1016\/j.pharmthera.2022.108116_bb0750","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1093\/eurheartj\/ehz587","article-title":"The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: A cohort study","volume":"40","author":"van\u2019t Klooster","year":"2019","journal-title":"European Heart Journal"},{"issue":"30","key":"10.1016\/j.pharmthera.2022.108116_bb0755","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1093\/eurheartj\/ehz350","article-title":"Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans","volume":"40","author":"Thijssen","year":"2019","journal-title":"European Heart Journal"},{"issue":"18","key":"10.1016\/j.pharmthera.2022.108116_bb0760","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1089\/ars.2016.6930","article-title":"From molecular mechanisms to clinical management of antineoplastic drug-induced cardiovascular toxicity: A translational overview","volume":"30","author":"Tocchetti","year":"2019","journal-title":"Antioxidants and Redox Signaling"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108116_bb0765","first-page":"2933","article-title":"Biomarkers of inflammation, hypercoagulability and endothelial injury predict early asymptomatic doxorubicin-induced cardiotoxicity in breast cancer patients","volume":"10","author":"Todorova","year":"2020","journal-title":"American Journal of Cancer Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108116_bb0770","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1371\/journal.pone.0058421","article-title":"Comparative cardiac toxicity of anthracyclines in vitro and in vivo in the mouse","volume":"8","author":"Toldo","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108116_bb0775","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00418-004-0696-7","article-title":"Reactive oxygen species in vascular biology: Implications in hypertension","volume":"122","author":"Touyz","year":"2004","journal-title":"Histochemistry and Cell Biology"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108116_bb0780","first-page":"348","article-title":"Administration of a TLR9 inhibitor attenuates the development and progression of heart failure in mice","volume":"4","author":"Ueda","year":"2019","journal-title":"JACC: Basic to Translational Science"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108116_bb0785","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1161\/CIRCINTERVENTIONS.113.001049","article-title":"Physiological basis and long-term clinical outcome of discordance between fractional flow reserve and coronary flow velocity reserve in coronary stenoses of intermediate severity","volume":"7","author":"Van De Hoef","year":"2014","journal-title":"Circulation. Cardiovascular Interventions"},{"issue":"38","key":"10.1016\/j.pharmthera.2022.108116_bb0790","doi-asserted-by":"crossref","first-page":"11293","DOI":"10.1021\/bi971475e","article-title":"Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin","volume":"36","author":"V\u00e1squez-Vivar","year":"1997","journal-title":"Biochemistry"},{"issue":"3\u20134","key":"10.1016\/j.pharmthera.2022.108116_bb0795","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.vph.2010.05.002","article-title":"Paclitaxel chemotherapy and vascular toxicity as assessed by flow-mediated and nitrate-mediated vasodilatation","volume":"53","author":"Vassilakopoulou","year":"2010","journal-title":"Vascular Pharmacology"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108116_bb0800","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/cncr.23389","article-title":"Cardiovascular risk in long-term survivors of testicular cancer","volume":"112","author":"Vaughn","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0805","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3389\/fimmu.2015.00422","article-title":"DAMPs from cell death to new life","volume":"6","author":"V\u00e9n\u00e9reau","year":"2015","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108116_bb0810","first-page":"563","article-title":"Radiation-induced endothelial vascular injury: A review of possible mechanisms","volume":"3","author":"Venkatesulu","year":"2018","journal-title":"JACC: Basic to Translational Science"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108116_bb0815","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00280-013-2260-4","article-title":"The role of antioxidants in the era of cardio-oncology","volume":"72","author":"Vincent","year":"2013","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108116_bb0820","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1161\/01.CIR.0000140262.20831.8F","article-title":"Serum myeloperoxidase levels independently predict endothelial dysfunction in humans","volume":"110","author":"Vita","year":"2004","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.pharmthera.2022.108116_bb0825","doi-asserted-by":"crossref","first-page":"6631","DOI":"10.1158\/0008-5472.CAN-15-3034","article-title":"Doxorubicin-induced systemic inflammation is driven by upregulation of toll-like receptor TLR4 and endotoxin leakage","volume":"76","author":"Wang","year":"2016","journal-title":"Cancer Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108116_bb0830","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00279-2020","article-title":"Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors","volume":"56","author":"Weatherald","year":"2020","journal-title":"European Respiratory Journal"},{"issue":"43","key":"10.1016\/j.pharmthera.2022.108116_bb0835","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1093\/eurheartj\/ehy167","article-title":"Long-term heart-specific mortality among 347 476 breast cancer patients treated with radiotherapy or chemotherapy: A registry-based cohort study","volume":"39","author":"Weberpals","year":"2018","journal-title":"European Heart Journal"},{"issue":"18","key":"10.1016\/j.pharmthera.2022.108116_bb0840","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/eurheartj\/ehu047","article-title":"Mitochondrial damage-associated molecular patterns and vascular function","volume":"35","author":"Wenceslau","year":"2014","journal-title":"European Heart Journal"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108116_bb0845","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1242\/bio.020362","article-title":"Cardiotoxic drugs Herceptin and doxorubicin inhibit cardiac microvascular endothelial cell barrier formation resulting in increased drug permeability","volume":"5","author":"Wilkinson","year":"2016","journal-title":"Biology Open"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108116_bb0850","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1440-1681.2004.04074.x","article-title":"Arterial stiffness, endothelial function and novel pharmacological approaches","volume":"31","author":"Wilkinson","year":"2004","journal-title":"Clinical and Experimental Pharmacology and Physiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108116_bb0855","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bbagen.2005.10.012","article-title":"The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction","volume":"1760","author":"Wolf","year":"2006","journal-title":"Biochimica et Biophysica Acta - General Subjects"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108116_bb0860","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1006\/jmcc.2002.2110","article-title":"Adriamycin-induced cardiomyocyte and endothelial cell apoptosis: In vitro and in vivo studies","volume":"34","author":"Wu","year":"2002","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0865","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00395-012-0267-3","article-title":"Role of HMGB1 in doxorubicin-induced myocardial apoptosis and its regulation pathway","volume":"107","author":"Yao","year":"2012","journal-title":"Basic Research in Cardiology"},{"issue":"24","key":"10.1016\/j.pharmthera.2022.108116_bb0870","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108116_bb0875","doi-asserted-by":"crossref","first-page":"192","DOI":"10.18632\/aging.100876","article-title":"miR-320a mediates doxorubicin-induced cardiotoxicity by targeting VEGF signal pathway","volume":"8","author":"Yin","year":"2016","journal-title":"Aging"},{"key":"10.1016\/j.pharmthera.2022.108116_bb0880","doi-asserted-by":"crossref","first-page":"9874109","DOI":"10.1155\/2018\/9874109","article-title":"The role of Toll-like receptor signaling in the progression of heart failure","volume":"2018","author":"Yu","year":"2018","journal-title":"Mediators of Inflammation"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108116_bb0885","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/1535370217746383","article-title":"Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients","volume":"243","author":"Yu","year":"2018","journal-title":"Experimental Biology and Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108116_bb0890","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/annonc\/mdw604","article-title":"Causes of death among cancer patients","volume":"28","author":"Zaorsky","year":"2017","journal-title":"Annals of Oncology"},{"issue":"7285","key":"10.1016\/j.pharmthera.2022.108116_bb0895","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature08780","article-title":"Circulating mitochondrial DAMPs cause inflammatory responses to injury","volume":"464","author":"Zhang","year":"2010","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.pharmthera.2022.108116_bb0900","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1001\/jama.286.17.2136","article-title":"Association between myeloperoxidase levels and risk of coronary artery disease","volume":"286","author":"Zhang","year":"2001","journal-title":"Journal of the American Medical Association"},{"issue":"2\u20133","key":"10.1016\/j.pharmthera.2022.108116_bb0905","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejphar.2010.06.024","article-title":"Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity","volume":"643","author":"Zhu","year":"2010","journal-title":"European Journal of Pharmacology"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822000109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822000109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:22:49Z","timestamp":1759011769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725822000109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":182,"alternative-id":["S0163725822000109"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108116","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endothelial dysfunction as a complication of anti-cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108116","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108116"}}